Humulin I Kwikpen (Isophane) (Insulin Human (Rdna))

Humulin I Kwikpen is a pre‑filled, disposable KwikPen containing insulin human (isophane), an intermediate‑acting insulin analogue supplied in a standard concentration for subcutaneous injection. The product is marketed in the European Union and requires a prescription. It delivers a consistent dose of recombinant human insulin to help regulate blood glucose in people with diabetes, and is designed for easy self‑administration through a single‑step activation mechanism.

Humulin I Kwikpen is indicated for the management of hyperglycemia in adults and children with diabetes.

- Type 1 diabetes mellitus as part of a basal‑bolus regimen. - Type 2 diabetes mellitus when basal insulin is required. - Adjunct therapy with rapid‑acting insulin analogues to achieve target glucose levels. - Use during periods of increased insulin resistance such as illness or steroid therapy. - Replacement therapy in patients transitioning from other intermediate‑acting insulins.

Adverse reactions to Humulin I Kwikpen may vary in frequency and severity.

Common: - Mild to moderate hypoglycemia, presenting as shakiness, sweating, or dizziness. - Local injection‑site reactions such as erythema, swelling, itching or bruising. - Small, reversible changes in subcutaneous fat (lipodystrophy) at the site of administration. - Gradual weight gain that may accompany improved blood‑glucose control.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms, possible loss of consciousness or seizures. - Immediate hypersensitivity reactions, including urticaria, angio‑edema or anaphylactic shock. - Generalized edema or fluid retention leading to peripheral swelling. - Development of painful lipohypertrophy or large indurated nodules at injection sites.

Before using Humulin I Kwikpen, patients and clinicians should consider several precautionary measures to ensure safe and effective therapy.

- Verify blood glucose levels before each injection to avoid hypoglycemia. - Rotate injection sites within the abdomen, thigh or upper arm to reduce lipodystrophy. - Do not use the pen if the solution is cloudy, discolored, or contains particles. - Adjust dose during periods of illness, increased physical activity, or when taking corticosteroids. - Monitor for signs of allergic reaction, especially after the first few administrations. - Use with caution in patients with renal or hepatic impairment, as insulin clearance may be altered. - Pregnant or breastfeeding women should discuss risks and benefits with their healthcare provider.

Humulin I Kwikpen can interact with other medications, affecting glucose control or increasing the risk of adverse events.

Avoid: - Concomitant use of other insulin products or insulin secretagogues without dose adjustment, which may cause severe hypoglycemia. - Beta‑blockers that mask hypoglycemia symptoms, making detection difficult.

Use with caution: - Oral antidiabetic agents (e.g., metformin, sulfonylureas) that may potentiate insulin’s glucose‑lowering effect. - Corticosteroids, which can increase insulin resistance and require dose escalation. - Diuretics, especially thiazides, that may raise blood glucose levels. - Alcohol consumption, which can cause unpredictable glucose fluctuations.